JP2024522494A5 - - Google Patents

Info

Publication number
JP2024522494A5
JP2024522494A5 JP2023572751A JP2023572751A JP2024522494A5 JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5 JP 2023572751 A JP2023572751 A JP 2023572751A JP 2023572751 A JP2023572751 A JP 2023572751A JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5
Authority
JP
Japan
Prior art keywords
disease
compound according
disorder
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023572751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522494A (ja
JP7705963B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/064995 external-priority patent/WO2022253936A1/en
Publication of JP2024522494A publication Critical patent/JP2024522494A/ja
Priority to JP2025051003A priority Critical patent/JP2025098157A/ja
Publication of JP2024522494A5 publication Critical patent/JP2024522494A5/ja
Application granted granted Critical
Publication of JP7705963B2 publication Critical patent/JP7705963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023572751A 2021-06-04 2022-06-02 トリアジン誘導体およびがんの処置におけるその使用 Active JP7705963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051003A JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21177660 2021-06-04
EP21177660.4 2021-06-04
EP21188639 2021-07-30
EP21188639.5 2021-07-30
EP21215875 2021-12-20
EP21215875.2 2021-12-20
PCT/EP2022/064995 WO2022253936A1 (en) 2021-06-04 2022-06-02 Triazine derivatives and their use in the treatment of cancer.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051003A Division JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Publications (3)

Publication Number Publication Date
JP2024522494A JP2024522494A (ja) 2024-06-21
JP2024522494A5 true JP2024522494A5 (enExample) 2025-04-03
JP7705963B2 JP7705963B2 (ja) 2025-07-10

Family

ID=82115763

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572751A Active JP7705963B2 (ja) 2021-06-04 2022-06-02 トリアジン誘導体およびがんの処置におけるその使用
JP2025051003A Pending JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051003A Pending JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Country Status (23)

Country Link
US (3) US20240132471A1 (enExample)
EP (1) EP4347571B1 (enExample)
JP (2) JP7705963B2 (enExample)
KR (1) KR20240019083A (enExample)
AR (1) AR126053A1 (enExample)
AU (1) AU2022287224A1 (enExample)
BR (1) BR112023025318A2 (enExample)
CA (1) CA3216026A1 (enExample)
CL (1) CL2023003491A1 (enExample)
CO (1) CO2023016212A2 (enExample)
CR (1) CR20230566A (enExample)
DK (1) DK4347571T3 (enExample)
ES (1) ES3072832T3 (enExample)
FI (1) FI4347571T3 (enExample)
HR (1) HRP20260777T1 (enExample)
IL (1) IL307201A (enExample)
LT (1) LT4347571T (enExample)
MA (1) MA64830B1 (enExample)
MX (1) MX2023013998A (enExample)
PE (1) PE20240928A1 (enExample)
RS (1) RS68198B1 (enExample)
SM (1) SMT202600264T1 (enExample)
WO (1) WO2022253936A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
EP4347571B1 (en) * 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
MX2024008548A (es) * 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
JP2025523930A (ja) * 2022-07-21 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US20260167637A1 (en) * 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
JP2025540202A (ja) * 2022-12-07 2025-12-11 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物
EP4683918A1 (en) * 2023-03-20 2026-01-28 Insilico Medicine IP Limited Nlrp3 inflammasome inhibitors and uses thereof
JP2026509587A (ja) * 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 トリアジン化合物およびその使用
CN120958000A (zh) * 2023-04-19 2025-11-14 豪夫迈·罗氏有限公司 噁唑并[4,5-b]吡嗪和噁唑并[4,5-b]吡啶衍生物作为nlrp3抑制剂用于治疗例如炎症性疾病
JP2026514799A (ja) * 2023-04-19 2026-05-13 エフ． ホフマン－ラ ロシュ アーゲー 炎症性疾患の処置のためのｎｌｐｒ３阻害剤としての５－［５－（２－ヒドロキシフェニル）オキサゾロ［４，５－ｂ］ピリジン－２－イル］ピペリジン－２－オン誘導体
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
CN121586712A (zh) * 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025046419A1 (ko) * 2023-08-25 2025-03-06 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025252772A1 (en) * 2024-06-06 2025-12-11 F. Hoffmann-La Roche Ag Triazine derivatives
WO2026046981A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol
WO2026067453A1 (en) * 2024-09-25 2026-04-02 Insilico Medicine Ip Limited Novel compounds as nlrp3 inflammasome inhibitors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) * 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
BR112020019373A2 (pt) * 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
WO2020163248A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
EP4347571B1 (en) * 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CN115433163A (zh) 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
PL4363406T3 (pl) 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
MX2024008548A (es) 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
KR20250005125A (ko) 2022-03-25 2025-01-09 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
CN120152974A (zh) 2022-10-26 2025-06-13 天维生物制药有限公司 缩环哒嗪衍生物
CN115621720B (zh) * 2022-10-27 2026-07-07 永道射频技术股份有限公司 一种应用于rfid读写器的全息超材料阵列天线
US20260167637A1 (en) 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
US20260200914A1 (en) 2022-12-28 2026-07-16 Astrazeneca Ab Nlrp3 inflammasome inhibitors
WO2024169858A1 (zh) 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途

Similar Documents

Publication Publication Date Title
JP2022096662A5 (enExample)
JP2024540445A5 (enExample)
JP6505013B2 (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
US20240374595A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
JP2020532506A5 (enExample)
JP5600685B2 (ja) ジペプトイドプロドラッグおよびそれらの使用
JP2024517917A5 (enExample)
JP2020507589A5 (enExample)
JP2023543059A5 (enExample)
JP2007524683A5 (enExample)
JP2019517455A5 (enExample)
JP2017537158A5 (enExample)
CN1794988B (zh) 用于治疗血管渗透性过高疾病的组合物
JP2005515172A5 (enExample)
JP2022008860A5 (enExample)
IL196129A (en) Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis
JP2013530179A5 (enExample)
JP2013544276A5 (enExample)
CN1378541A (zh) c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂
JP2012512203A (ja) アミノ酸エステルのプロドラッグおよびその使用
JP2019500387A5 (enExample)
JP2024518556A5 (enExample)
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
JP2016540811A5 (enExample)
JP2008517923A5 (enExample)